Emergent BioSolutions (EBS) PT Lowered to $23 at Cantor Fitzgerald
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.90 --0%
Rating Summary:
12 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Rating Summary:
12 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 33 | New: 6
Join SI Premium – FREE
Cantor Fitzgerald analyst Brandon Folkes lowered the price target on Emergent BioSolutions (NYSE: EBS) to $23.00 (from $33.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Emergent BioSolutions (EBS) Misses Q3 EPS by 23c
- Navient Corporation (NAVI) PT Raised to $9 at JPMorgan
- Limbach Holdings (LMB) PT Raised to $55 at JPMorgan
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
